FHTXHealthcare · BiotechnologyThe 10 Wall Street analysts covering Foghorn Therapeutics, Inc. hold a median 12-month price target of $5 — +139.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 40 of 100 as at 29 Oct 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Foghorn Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (91): Sales and profits are climbing, and climbing faster than before.
Issuance (14): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on FHTX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +139.2% from it.
Of the 20 most recent actions, 0 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 2 Oct 2026 | BTIG | Downgrade | Neutral | — |
| 2 Oct 2026 | Guggenheim | Maintains | Buy | $12 → $5.00 |
| 2 Oct 2026 | HC Wainwright & Co. | Maintains | Buy | $13 → $5.00 |
| 2 Oct 2026 | TD Cowen | Downgrade | Hold | — |
| 2 Oct 2026 | Wedbush | Downgrade | Neutral | $10 → $2.00 |
| 12 Mar 2026 | Wedbush | Reiterates | Outperform | — |
| 12 Mar 2026 | Wedbush | Reiterates | Outperform | $10 |
| 10 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 10 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | $13 |
| 17 Feb 2026 | Jefferies | Maintains | Buy | — |
| 18 Dec 2025 | BTIG | Initiates | Buy | — |
| 4 Dec 2025 | Stifel | Initiates | Buy | — |
| 7 Nov 2025 | Guggenheim | Initiates | Buy | — |
| 15 May 2025 | JMP Securities | Reiterates | Market Outperform | — |
| 30 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 30 Apr 2025 | JMP Securities | Reiterates | Market Outperform | — |
| 23 Apr 2025 | JMP Securities | Initiates | Market Outperform | — |
| 7 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 30 Jan 2025 | B. Riley Securities | Initiates | Buy | — |
| 17 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
FHTX appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 29 Oct 2026, Foghorn Therapeutics, Inc. returned −50.6% against +13.1% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 85% of US stocks
Cheaper than 36% of US stocks
Cheaper than 95% of US stocks
Cheaper than 62% of US stocks
Higher than 93% of US stocks
Higher than 85% of US stocks
Higher than 16% of US stocks
Higher than 3% of US stocks
Higher than 94% of US stocks
Higher than 19% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Foghorn Therapeutics, Inc. has a market value of $121.7M and an enterprise value of −$2.7M.
Revenue in the twelve months to 30 June 2026: $36.7M. The latest quarter grew 112.7% year on year.
Net income over the same four quarters: −$64.6M, a −175.8% net margin.
Free cash flow in the twelve months to 30 June 2026: −$84.3M.
Trailing P/E: −1.7×; forward P/E: −2.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Foghorn Therapeutics, Inc. employs 106 people — $347K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Foghorn Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research says Foghorn Therapeutics has two key factors it views as supporting a likely earnings beat in the company’s upcoming report.
Why it matters — FHTX watchers may note the source’s expectations ahead of the upcoming earnings report.
Business Wire reported that SBS Law is offering FHTX investors with $100,000 in losses an opportunity to join a fraud investigation concerning Foghorn Therapeutics Inc.
Why it matters — The notice concerns a fraud investigation and may be relevant to FHTX investors following legal developments.
Foghorn Therapeutics, Inc. (NASDAQ:FHTX) stock is trading lower on Thursday with unusually high session volume of 9.158 million shares, compared to an average volume of 377,206, according to Benzinga Pro data. The company is pivoting its pipeline after ending its collaboration deal with Eli Lilly.
Why it matters — FHTX watchers would care because the stock is trading down on a sharp spike in volume following the company's pipeline pivot after the Eli Lilly deal ended, signaling significant investor reaction to the strategic shift.
Foghorn Therapeutics has discontinued development of an experimental cancer drug partnered with Eli Lilly after the treatment failed to show sufficient benefit in an early-stage trial. The company also plans to cut 40% of its workforce.
Why it matters — The discontinuation of a Lilly-partnered drug and the large workforce reduction signal a major setback in Foghorn's pipeline and operations for shareholders and investors watching the company.
Foghorn Therapeutics and Eli Lilly will not pursue any future collaborations following the dissolution of their cancer-drug partnership. As a result, Foghorn plans to cut roughly 40% of its workforce.
Why it matters — The end of the Lilly partnership and the significant job cuts signal a major restructuring and loss of a key collaboration for FHTX.
The 10 Wall Street analysts covering Foghorn Therapeutics, Inc. have a median 12-month price target of $5, with estimates ranging from $2 to $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 10 analysts covering Foghorn Therapeutics, Inc., 5 rate it a Buy, 5 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Foghorn Therapeutics, Inc. 40 out of 100 across roughly 4,600 US stocks as at 29 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 29 Oct 2026, Foghorn Therapeutics, Inc. ranks 40 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (91 of 100).
No one can know that. What the data says: the median 12-month target from 10 analysts implies +139.2% from the last close, and Ticker Nerd's factor model ranks Foghorn Therapeutics, Inc. 40 out of 100 as at 29 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Foghorn Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for FHTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $5 over the next 12 months.
Foghorn Therapeutics, Inc. returned -50.6% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Foghorn Therapeutics Inc. is a clinical-stage biotechnology company focused on discovering and developing medicines that correct abnormal gene expression.
The most recent item we track (Zacks Investment Research, 28 Oct 2026): "Foghorn Therapeutics Inc. (FHTX) Expected to Beat Earnings Estimates: Should You Buy?". Zacks Investment Research says Foghorn Therapeutics has two key factors it views as supporting a likely earnings beat in the company’s upcoming report.
Foghorn Therapeutics Inc. is a clinical-stage biotechnology company focused on discovering and developing medicines that correct abnormal gene expression. Foghorn Therapeutics Inc. uses its proprietary Gene Traffic Control platform to study the chromatin regulatory system, a core mechanism that influences how genes are activated or silenced in cells. Its current programs are centered on oncology, with efforts directed at genetically defined cancers and other serious diseases linked to chromatin-driven dependencies. The company’s research and development activities include precision therapeutics designed to identify and validate drug targets within this regulatory network, supporting the creation of targeted treatments for hard-to-address diseases. Headquartered in Watertown, Massachusetts, Foghorn Therapeutics Inc. plays a specialized role in the biotechnology market as a developer of novel, mechanism-based therapies.
CEO Mr. Adrian H. B. Gottschalk · 106 employees · United States · https://foghorntx.com
